Gynecologic cancer intergroup (GCIG) consensus review for clear cell carcinoma of the ovary

International Journal of Gynecological Cancer

Volumn 24, Issue 9, 2014, Pages S20-S25

  Okamoto, Aikou ^a   Glasspool, Rosalind M ^b   Mabuchi, Seiji ^c   Matsumura, Noriomi ^d   Nomura, Hiroyuki ^e   Itamochi, Hiroaki ^f   Takano, Masashi ^g   Takano, Tadao ^h   Susumu, Nobuyuki ^e   Aoki, Daisuke ^e   Konishi, Ikuo ^d   Covens, Alan ⁱ   Ledermann, Jonathan ^j   Mezzazanica, Delia ^k   Steer, Christopher ^l   Millan, David ^m   Mcneish, Iain A ⁿ   Pfisterer, Jacobus ^o   Kang, Sokbom ^p   Gladieff, Laurence ^p   Bryce, Jane ^q   Oza, Amit ^r   more..

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e KEIO UNIVERSITY   (Japan)

^f TOTTORI UNIVERSITY   (Japan)

^g NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^h TOHOKU UNIVERSITY HOSPITAL   (Japan)

ⁱ SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^j UNIVERSITY COLLEGE LONDON   (United Kingdom)

^k NATIONAL CANCER INSTITUTE   (Italy)

^l Border Medical Oncology Australia   (Australia)

^m UNIVERSITY OF GLASGOW   (United Kingdom)

ⁿ Gynecologic Oncology Center Kiel   (Germany)

^o National Cancer Center   (South Korea)

^p INSTITUT CLAUDIUS REGAUD   (France)

^q NATIONAL CANCER INSTITUTE   (Italy)

^r PRINCESS MARGARET HOSPITAL   (Canada)

more..

Author keywords

ARID1A; Cisplatin; Clear cell carcinoma of the ovary (CCC); Cytoreductive surgery; Deep venous thrombosis; Ethnics; Glycogen; Hepatocyte nuclear factor 1q; Irinotecan hydrochloride; KRAS; Paclitaxel; PI3K AKT mTOR; PIK3CA; Platinum; PPM1D; PPP2R1A; Pulmonary embolism; WT1

Indexed keywords

CARBOPLATIN; CISPLATIN; IRINOTECAN; MAMMALIAN TARGET OF RAPAMYCIN; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURGERY; CLEAR CELL CARCINOMA; CONSENSUS; CYTOREDUCTIVE SURGERY; DISEASE SEVERITY; GENE MUTATION; HISTOPATHOLOGY; HUMAN; MEDICAL SOCIETY; METASTASIS; OVARY CARCINOMA; PRIORITY JOURNAL; REVIEW; ADENOCARCINOMA, CLEAR CELL; FEMALE; MULTIMODALITY CANCER THERAPY; ONCOLOGY; OVARIAN NEOPLASMS; PATHOLOGY; PRACTICE GUIDELINE;

ADENOCARCINOMA, CLEAR CELL; COMBINED MODALITY THERAPY; CONSENSUS; FEMALE; HUMANS; MEDICAL ONCOLOGY; OVARIAN NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; SOCIETIES, MEDICAL;

EID: 84922377545     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0000000000000289     Document Type: Review

References (37)

1. Sugiyama T, Kamura T, Kigawa J, et al. Clinical characteristics of clear cell carcinoma of the ovary: A distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer. 2000;88:2584-2589.
2. del Carmen MG, Birrer M, Schorge JO. Clear cell carcinoma of the ovary: A review of the literature. Gynecol Oncol. 2012;126:481-490.
3. Anglesio MS, Carey MS, Köbel M, et al. Clear cell carcinoma of the ovary: A report from the first Ovarian Clear Cell Symposium, June 24th, 2010. Gynecol Oncol. 2011;121:407-415.
4. Japanese Gynecologic Cancer Committee. Annual report on Japanese gynecologic cancer committee. Acta Obstet Gynecol Jpn. 2012;64:1029-1141.
5. Recio FO, et al. Lack of improved survival plus increase in thromboembolic complications in patients with clear cell carcinoma of the ovary treated with platinum versus nonplatinum
6. Matsuura Y, et al. Thromboembolic complications in patients with clear cell carcinoma of the ovary. Gynecol Oncol. 2007;104:406-410.
7. McCluggage WG. Morphological subtypes of ovarian carcinoma: A review with emphasis on new developments and pathogenesis. Pathology. 2011;43:420-423.
8. McCluggage WG, Young RH. Immunohistochemistry as a diagnostic aid in the evaluation of ovarian tumors. Semin Diagn Pathol. 2005;22:3-32.
9. Tsuchiya A, Sakamoto M, Yasuda J, et al. Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol. 2003;163:2503-2512.
10. Kobel M, Kalloger SE, Boyd N, et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med. 2008;5:e232.
11. Wiegand KC, Shah SP, Al-Agha OM, et al. ARID1A mutations in endometriosis-Associated ovarian carcinomas. N Engl J Med. 2010;363:1532-1543.
12. Kuo KT, Mao TL, Jones S, et al. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol. 2009;174:1597-1601.
13. Tan DS, et al. PPM1D is a potential therapeutic target in ovarian clear cell carcinomas. Clin Cancer Res. 2009;15:2269-2280.
14. Jones S, et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science. 2010;330:228-231.
15. Tan DS, et al. Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomas. Clin Cancer Res. 2011;17:1521-1534.
16. Yamaguchi K, Mandai M, Oura T, et al. Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes. Oncogene. 2010;29:1741-1752.
17. Takano M, Sugiyama T, Yaegashi N, et al. The impact of complete surgical staging upon survival in early-stage ovarian clear cell carcinoma: A multi-institutional retrospective study. Int J Gynecol Cancer. 2009;19:1353-1357.
18. Magazzino F, Katsaros D, Ottaiano A, et al. Surgical and medical treatment of clear cell ovarian cancer: results from the multicenter Italian Trials in Ovarian Cancer (MITO) 9 retrospective study. Int J Gynecol Cancer. 2011;21:1063-1070.
19. Suzuki S, Kajiyama H, Shibata K, et al. Is there any association between retroperitoneal lymphadenectomy and survival benefit in ovarian clear cell carcinoma patients? Ann Oncol. 2008;19: 1284-1287.
20. Takano M, Kikuchi Y, Yaegashi N, et al. Clear cell carcinoma of the ovary: A retrospective multicentre experience of 254 patients with complete surgical staging. Br J Cancer. 2006;94:1369-1374.
21. Hoskins WJ, Bundy BN, Thigpen JT, et al. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: A Gynecologic Oncology Group study. Gynecol Oncol. 1992;47:159-166.
22. Satoh T, Hatae M, Watanabe Y, et al. Outcomes of fertility-sparing surgery for stage I epithelial ovarian cancer: A proposal for patient selection. J Clin Oncol. 2010;28:1727-1732.
23. Kajiyama H, Shibata K, Mizuno M, et al. Fertility-sparing surgery in patients with clear-cell carcinoma of the ovary: is it possible? Hum Reprod. 2011;26:3297-3302.
24. Takano M, et al. Less impact of adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: A retrospective Japan Clear Cell Carcinoma Study. Int J Gynecol Cancer. 2010;20:1506-1510.
25. Utsunomiya H, Akahira J, Tanno S, et al. Paclitaxel-platinum combination chemotherapy for advanced or recurrent ovarian clear cell adenocarcinoma: A multicenter trial. Int J Gynecol Cancer. 2006;16:52-56.
26. Takakura S, Takano M, Takahashi F, et al. Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: A JGOG study. Int J Gynecol Cancer. 2010;20:240-247.
27. Swenerton KD, Santos JL, Gilks CB, et al. Histotype predicts the curative potential of radiotherapy: The example of ovarian cancers. Ann Oncol. 2011;22:341-347.
28. Hoskins PJ, Le N, Gilks B, et al. Low-stage ovarian clear cell carcinoma: population-based outcomes in British Columbia, Canada, with evidence for a survival benefit as a result of irradiation. J Clin Oncol. 2012;30:1656-1662.
29. Kajiyama H, Shibata K, Mizuno M, et al. Postrecurrent oncologic outcome of patients with ovarian clear cell carcinoma. Int J Gynecol Cancer. 2012;22:801-806.
30. Jenison EL, Montag AG, Griffiths CT, et al. Clear cell adenocarcinoma of the ovary: A clinical analysis and comparison with serous carcinoma. Gynecol Oncol. 1989;32:65-71.
31. Ovarian Cancer Guideline (Version 1. 2013). NCCN Clinical Practice Guidelines in Oncology. Available at: http://www.nccn.org/professionals/physician-gls/pdf/ovarian.pdf.
32. Takano M, Sugiyama T, Yaegashi N, et al. Low response rate of second-line chemotherapy for recurrent or refractory clear cell carcinoma of the ovary: A retrospective Japan Clear Cell Carcinoma Study. Int J Gynecol Cancer. 2008;18:937-942.
33. Blackledge G, Lawton F, Redman C, et al. Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br J Cancer. 1989;59:650-653.
34. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol. 2010;28:3323-3329.
35. Ferrandina G, Ludovisi M, Lorusso D, et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol. 2008;26:890-896.
36. Mabuchi S, Hisamatsu T, Kimura T. Targeting mTOR signaling pathway in ovarian cancer. Curr Med Chem. 2011;18: 2960-2968.
37. Mabuchi S, Hisamatsu T, Kawase C, et al. The activity of trabectedin as a single agent or in combination with everolimus for clear cell carcinoma of the ovary. Clin Cancer Res. 2011;17:4462-4473.